Part One: Molecular Screening and Treatment in MDS, Mutant IDH as a Target, and Enasidenib
Part Two: Luspatercept in Lower Risk MDS: Updates from the PACE Study and Phase 2 Studies in Patients with Anemia

Managing MDS would like to recognize and thank Celgene Corporation for their educational support of

©2018 MediCom Worldwide, Inc. All rights reserved